Fulltext

Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)

Koeberle, D. ; Betticher, D. C. ; von Moos, R. ; Dietrich, D. ; Brauchli, P. ; Baertschi, D. ; Matter, K. ; Winterhalder, R. ; Borner, M. ; Anchisi, S. ; Moosmann, P. ; Kollar, A. ; Saletti, P. ; Roth, A. ; Frueh, M. ; Kueng, M. ; Popescu, R. A. ; Schacher, S. ; Hess, V. ; Herrmann, R.

In: Annals of Oncology, 2015, vol. 26, no. 4, p. 709-714

Aggiungi alla tua lista
    Titre
    • Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)
    Auteur
    • Koeberle, D.. Department of Oncology, Kantonsspital St Gallen, St Gallen
    • Betticher, D. C.. Department of Oncology, Hôpital Fribourgeois, Fribourg
    • von Moos, R.. Department of Oncology, Kantonsspital Chur, Chur
    • Dietrich, D.. SAKK Coordinating Centre, Bern
    • Brauchli, P.. SAKK Coordinating Centre, Bern
    • Baertschi, D.. SAKK Coordinating Centre, Bern
    • Matter, K.. Institute of Pharmaceutical Medicine/ECPM, Basel
    • Winterhalder, R.. Department of Oncology, Kantonsspital Luzern, Luzern
    • Borner, M.. Department of Oncology, Spitalzentrum Biel, Biel
    • Anchisi, S.. Department of Oncology, Hôpital de Sion, Sion
    • Moosmann, P.. Department of Oncology, Kantonsspital Aarau, Aarau
    • Kollar, A.. Department of Oncology, Inselspital Bern, Bern
    • Saletti, P.. Department of Oncology, IOSI, Bellinzona
    • Roth, A.. Department of Oncology, HCUG, Geneva
    • Frueh, M.. Department of Oncology, Kantonsspital St Gallen, St Gallen
    • Kueng, M.. Department of Oncology, Hôpital Fribourgeois, Fribourg
    • Popescu, R. A.. Department of Oncology, Hirslanden Klinik Aarau, Aarau
    • Schacher, S.. Department of Oncology, Kantonsspital Winterthur, Winterthur
    • Hess, V.. Department of Oncology, Universitätsspital Basel, Basel, Switzerland
    • Herrmann, R.. Department of Oncology, Universitätsspital Basel, Basel, Switzerland
    Type de document
    • Postprint
    Langue
    • Inglese
    Publié dans
    • Annals of Oncology, 2015, vol. 26, no. 4, p. 709-714. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:303472
    Summary
    In this trial, stopping bevacizumab after completion of induction chemotherapy was associated with a shorter time to progression, but no statistically significant difference in overall survival compared with the bevacizumab continuation strategy. Non-inferiority could not be demonstrated. Treatment costs are substantially higher for continuous bevacizumab treatment